EMA Confirms Rejection of Neurodegenerative Disease Drugs
The European Medicines Agency (EMA) has upheld an earlier recommendation to deny marketing authorization for Masitinib AB Science (masitinib), an oral treatment for amyotrophic lateral sclerosis (ALS). In a meeting on October 17, the EMA’s Committee for Medicinal Products for Human Use (CHMP) reaffirmed its concerns about the reliability of the data supporting the drug…
Read More
0
